Goldea Capital

Verizon gives customers more peace of mind with enhanced Home Device Protection service

Written by Customer Service on April 25, 2024. Posted in Public Companies.

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) — Research has shown that the average U.S. household has over $11,000 worth of home technology products1. As the number of devices we rely on at home continues to increase, so does the need to protect them. For $25/month (plus applicable taxes), customers can repair and replace an unlimited number of eligible home technology products such as TVs, tablets, laptops, wearables and gaming devices with Verizon Home Device Protect.2 Beginning April 25, customers with Verizon Home Device Protect will gain access to new benefits and services at no additional cost, including: Expanded Protection: Coverage now includes Wi-Fi-enabled home healthcare tech (pulse oximeters, EKGs, blood pressure monitors), smart mops and vacuums, pet-care items and advanced gaming accessories. Second Residence Coverage:...

SYLA Technologies Announces Gain on Sales of Investment Securities

Written by Customer Service on April 25, 2024. Posted in Public Companies.

TOKYO, April 25, 2024 (GLOBE NEWSWIRE) — SYLA Technologies Co., Ltd. (NASDAQ: SYT) (“SYLA” or “the Company”), operator of the largest membership real estate crowd-funding platform in Japan, Rimawari-kun, announced the sale of a segment of its investment securities holdings, resulting in a profit of 96 million yen. On April 11, 2024, SYLA executed the sale of one listed stock from its investment portfolio, resulting in a total gain on sales of 96 million yen. SYLA intends to utilize the net proceeds to enhance asset efficiency and fortify the company’s financial structure. The sale will be recorded as other income for both the consolidated and non-consolidated accounting periods of the fiscal year ending December 31, 2024. The effects of the sale, alongside other factors, are currently being reviewed. Any necessary adjustments to...

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Written by Customer Service on April 25, 2024. Posted in Public Companies.

Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. The Company will report results from this trial and host a call with study clinical cardiology leadership to review the opportunity, early positive results, and randomized study on Tuesday, April 30, 2024, at 3:00 PM ET. Participants can register for the conference by navigating to https://dpregister.com/sreg/10188810/fc71df44d6. Please note that...

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Written by Customer Service on April 25, 2024. Posted in Public Companies.

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of 986,000 shares of its common stock at an offering price of $9.84 per share of common stock and accompanying warrant. The warrants include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzheimer’s Disease program (as further described below). The offering was priced at-the-market under Nasdaq rules based on the average of the previous 5-days’ closing prices, or $9.84 per share which includes...

Calavo Growers, Inc. Provides Update to Shareholders

Written by Customer Service on April 25, 2024. Posted in Public Companies.

SANTA PAULA, Calif., April 25, 2024 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq: CVGW) (“Calavo” or the “Company”), a global avocado industry leader and provider of convenient, ready-to-eat fresh food, yesterday at its Annual Meeting of Shareholders said in a business update that: The Company has made significant progress toward completing the proposed sale of the Fresh Cut business (formerly “RFG”) and related real property and expects to close in May 2024 As previously shared, the expected uses of sale proceeds would include paying down debt and returning cash to shareholders The Company’s internal investigation into potential Foreign Corrupt Practices Act violations in Mexico is winding down and the Company will share more with investors when it is able to do so About Calavo Growers, Inc. Calavo Growers, Inc. (Nasdaq:...

Opthea to Present at the OIS Retina Innovation Summit at ARVO

Written by Customer Service on April 25, 2024. Posted in Public Companies.

MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington. OIS Retina Innovation Summit Details Session Innovation Showcase Date: Saturday, May 4, 2024 Time: 8:35 to 9:50 a.m. PDT Presenter: Frederic Guerard, PharmD, CEO About Opthea Opthea (ASX/NASDAQ:OPT)...

Medigene presents streamlined 6-day, high stemness TCR-T therapy production process

Written by Customer Service on April 25, 2024. Posted in Public Companies.

Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents a comprehensive overview of its lead candidate MDG1015, a first-in-class 3rd generation T cell receptor engineered T cell (TCR-T) therapy, at CHI’s 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London. MDG1015, which is advancing towards the clinic, targets NY-ESO-1 / LAGE-1a (New York esophageal squamous cell carcinoma 1 / L Antigen Family Member-1a) and is armored and enhanced by the PD1-41BB costimulatory switch protein The presentation with the title “MDG1015: a 3rd Generation TCR-T Therapy Incorporating the PD1-41BB Costimulatory Switch Protein, Advancing to the Clinic”...

Lakeland Financial Reports First Quarter Net Income of $23.4 Million and 5% Annualized Average Loan Growth

Written by Customer Service on April 25, 2024. Posted in Earnings Releases And Operating Results.

WARSAW, Ind., April 25, 2024 (GLOBE NEWSWIRE) — Lakeland Financial Corporation (Nasdaq Global Select/LKFN), parent company of Lake City Bank, today reported net income of $23.4 million for the three months ended March 31, 2024, which represents a decrease of $877,000, or 4%, compared with net income of $24.3 million for the three months ended March 31, 2023. Diluted earnings per share were $0.91 for the first quarter of 2024 and decreased 3% compared to $0.94 for the first quarter of 2023. On a linked quarter basis, net income decreased $6.2 million, or 21%, from fourth quarter 2023 net income of $29.6 million. Diluted earnings per share decreased from $1.16, or 22%. Net income for the first quarter of 2024 benefited from the recognition of $1.0 million in additional insurance recoveries associated with the wire fraud loss that...

First Merchants Corporation Announces First Quarter 2024 Earnings Per Share

Written by Customer Service on April 25, 2024. Posted in Earnings Releases And Operating Results.

MUNCIE, Ind., April 25, 2024 (GLOBE NEWSWIRE) — First Merchants Corporation (NASDAQ – FRME) First Quarter 2024 Highlights: Net income available to common stockholders was $47.5 million and diluted earnings per common share totaled $0.80 compared to $63.6 million and $1.07 in the first quarter of 2023, and $42.0 million and $0.71 in the fourth quarter of 2023. Net income and diluted earnings per common share, excluding non-core charges of $3.5 million incurred during the quarter, totaled $50.1 million and $0.85, respectively. Strong capital position with Common Equity Tier 1 Capital Ratio of 11.25 percent. Total loans declined $24.3 million, or 0.8 percent annualized on a linked quarter basis, but increased $346.4 million, or 2.8 percent during the last twelve months when excluding the impact of a non-relationship commercial...

Hanmi Financial Declares Cash Dividend of $0.25 per share and Announces New Share Repurchase Authorization

Written by Customer Service on April 25, 2024. Posted in Public Companies.

LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) — Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”), the parent company of Hanmi Bank (the “Bank”), today announced that its Board of Directors declared a cash dividend on its common stock for the 2024 second quarter of $0.25 per share. The dividend will be paid on May 22, 2024, to stockholders of record as of the close of business on May 6, 2024. In addition, the Board of Directors today approved a new stock repurchase program. Under the new repurchase program, the Company may repurchase up to 5% of its outstanding shares, or approximately 1.5 million shares of its common stock. “We believe Hanmi’s long-term growth prospects are attractive, and today’s new share repurchase authorization serves as evidence of the Company’s ongoing focus on its capital allocation priorities”, said...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice